Alistair Macdonald has been appointed as Worldwide Clinical Trials’ new Chief Executive Officer (CEO). He takes over from Peter Benton, who is retiring after more than a decade as president and CEO of the company.
Benton will remain at Worldwide , a global contract research organisation (CRO), as Senior Advisor, to ensure a seamless transition for employees and customers.
Matt Jennings, Executive Chairman of Worldwide and Operating Partner of Kohlberg, said: “Alistair brings the right experience to lead this next chapter – a proven growth leader who knows how to scale organisations while preserving what makes them exceptional…”
Macdonald’s previous roles in the clinical research industry have included clinical development, oncology and business development. Most recently, he was Operating Partner at GHO Capital and prior to that he was CEO of Syneos Health. He has also held board positions at Association of Clinical Research Organizations (ACRO), Medicines Discovery Catapult, Seqens, Eliquent, OncImmune and Klick Health.
“I’m honoured to join Worldwide at such a pivotal moment in the growth trajectory of the business,” added Macdonald, “and I look forward to working closely with our talented teams.”
Commenting on Peter Benton’s retirement after 11 years, Jennings said: “We are grateful to Peter for his visionary leadership and unwavering commitment to excellence while at the helm of Worldwide. His legacy will continue to shape Worldwide’s future as we welcome Alistair as our next CEO.”